AbbVie Inc. (ABBV) Stock: Price, Forecast & Analyst Target
AbbVie Inc. (ABBV) — MoonshotScore 81/100 (Exceptional band), calculated Nov 16, 2026. Price $294.67 (-0.12%), as of the Nov 16, 2026 trading session; market cap $521B. Expected results Feb 3, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 48.36× (market value Nov 16, 2026; cash Sep 30, 2026) · expected results Feb 3, 2027
AbbVie Inc. · ABBV · NYSE · Healthcare · Drug Manufacturers - General
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered): AbbVie sells prescription medicines across immunology, oncology, neuroscience, eye care and other therapeutic markets, with Skyrizi and Rinvoq now far more important to revenue than Humira. The decisive issue is whether those growing immunology franchises can sustain rising sales and cash generation while AbbVie carries substantial debt and funds a broad research portfolio.
Price as of Nov 16, 2026
Key Statistics
MoonshotScore v2 · AbbVie (ABBV)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality and a strong balance sheet, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Sound; Valuation: Full; Growth Durability: Growing; Momentum: Surging.
- quarterly revenue $17.40B (Q3 FY2026, quarter ended Sep 2026)
- EPS beat 7 of the last 8 reports
- expected results Feb 3, 2027
Helping: business quality, balance-sheet strength, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 82 | Exceptional | |
| 82 | Exceptional | |
| 81 | Exceptional | |
| 81 | Exceptional | |
| 81 | Exceptional | |
| 81 | Exceptional |
The score moved from 82 in the stored Nov 15, 2026 snapshot to 81 in the current publication computed Nov 16, 2026 (-1); the largest pillar moves were Valuation -2 and Momentum -2.
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $294.672.7% below its all-time high of $302.93 () | |
| Change on the day | -0.12% | |
| 52-week range | $190.75–$302.93 | |
| Market capitalisation | $521B | |
| Price / earnings (trailing) | 50.44 | |
| Shares traded on the day | 4.69M | |
| Beta (volatility vs the S&P 500) | 0.28 | |
| Dividends per share (last 12 months) | $6.92 | |
| Dividend yield (last 12 months) | 2.35% |
Why AbbVie scores 81
Share price, last 12 months +34.1%
$218.71 $293.30
What the price assumes
11.5% a year of free-cash-flow growth for ten years is what a $521.00B market value () asks for.
The price already assumes faster growth than the last 5 years delivered. Anything short of an acceleration leaves room to disappoint. It also runs ahead of the analysts' revenue path.
Reverse discounted cash flow: 10% discount rate, 3% growth after year ten, starting from trailing twelve months free cash flow of $18.87B. Inputs: FMP statements, estimates and quote.
How the stock reacts to earnings
EPS beat in 11 of the last 12 reports (2024–2026); the stock still fell the next session after 5 of those beats. Average first-session move: 4.9% either way.
- +2.2%Feb ’24
- -3.4%Apr ’24
- +5.1%Jul ’24
- +7.6%Oct ’24
- +8.2%Jan ’25
- +6.6%Apr ’25
- +3.1%Jul ’25
- -7.1%Oct ’25
- -2.9%Feb ’26
- +6.9%Apr ’26
- -4.8%Jul ’26
- -0.7%Oct ’26
Every report, with revenue and five-session moves
| Report | EPS | Revenue | Next session | 5 sessions |
|---|---|---|---|---|
| Beat | In line | -0.7% | +0.2% | |
| Beat | Beat | -4.8% | -4.4% | |
| Beat | Beat | +6.9% | +3.7% | |
| Beat | Beat | -2.9% | -2.1% | |
| Beat | Beat | -7.1% | -4.0% | |
| Beat | Beat | +3.1% | +5.0% | |
| Beat | Beat | +6.6% | +10.0% | |
| Miss | Beat | +8.2% | +8.5% | |
| Beat | Beat | +7.6% | +6.2% | |
| Beat | Beat | +5.1% | +7.7% | |
| Beat | Beat | -3.4% | -2.1% | |
| Beat | Beat | +2.2% | +3.9% |
Beating the estimate has not been enough: the stock fell after 5 of the last 11 beats. The bar it has to clear is the whisper number, not the published one.
Our track record on this stock
Since the score went from 82 to 81 while the share price moved +11.4% through .
| Date | Band | 3 months | 6 months | Call |
|---|---|---|---|---|
| Strong → Exceptional | — | — | — | |
| Exceptional → Strong | — | — | — | |
| Strong → Exceptional | — | — | — | |
| Exceptional → Strong | — | — | — | |
| Strong → Exceptional | — | — | — | |
| Exceptional → Strong | — | — | — |
None of the 6 band changes we have recorded has been graded yet; we grade each band change three months after it happens.
The crowd against our signals
- Analysts: 70% of 44 rate it a buy; the average target sits +4.8% from the price of $294.67.
- Last 90 days: 1 upgrade and 0 downgrades among 21 rating actions.
- Our signals: Exceptional band; strongest pillar Momentum (89), weakest Valuation (50).
Here we and the crowd agree. Where we differ is on price: our Valuation reading is more cautious than the analysts' targets.
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
We continue to forecast full year adjusted gross margin above 84% of sales, adjusted R&D expense of approximately $9.8 billion and adjusted SG&A expense of approximately $14.5 billion.
Scott Reents · Statement from
We also anticipate an adjusted operating margin of approximately 46.7% of sales, which includes a roughly 1.8% unfavorable impact from acquired IPR&D expense incurred through the third quarter.
Scott Reents · Statement from
How to read these dates
Events are in date order; the spacing is not a duration scale. A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.
Other perspectives
Council score for AbbVie (ABBV): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
5 lenses, 5 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 16, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 17, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Two of these lenses read this company less favourably than the MoonshotScore does: Griffin-style lens and Munger lens (margin of safety). Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as overvalued against its own estimate of value.
Readings on this page are from Nov 17, 2026, except a card that shows its own read date.
What is AbbVie (ABBV), and what does it report?
Short answer · as of
AbbVie is not simply a diversified drug manufacturer: its economics are increasingly anchored by Skyrizi and Rinvoq, while Humira has become a smaller part of the reported product mix. Therapeutic Botox, Vraylar and medicines spanning cancer, migraine, eye care and digestive disease add breadth, but immunology remains the largest visible revenue engine.
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered).
Reported revenue measures product sales across this portfolio, whereas reported profit also reflects heavy research and selling costs. Those expenses can make earnings much more volatile than demand for the medicines themselves.
What do the latest results show for AbbVie (ABBV)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of $17.40B.
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered).
The latest period showed a strong sequential rise in revenue, operating profit, net income and diluted earnings. Revenue and adjusted earnings also exceeded consensus expectations, extending a run of company-level sales beats.
The current product mix points to Skyrizi and Rinvoq as the commercial mechanism behind AbbVie's transition away from Humira dependence, but the available quarterly results do not assign the latest change to individual medicines. Research spending remained substantial, so the profit recovery reflects revenue growth and improved operating absorption alongside continued pipeline investment, not a retreat from development activity.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $17.40B Sep 30, 2026
- Latest quarter · R&D
- $2.78B Sep 30, 2026
- Latest quarter · SG&A
- $4.09B Sep 30, 2026
- Latest quarter · FMP standardized operating result
- $6.27B Sep 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | $17.40B | $2.78B | $4.09B | $6.27B |
| Jun 30, 2026 | $16.99B | $2.34B | $3.63B | $6.43B |
| Mar 31, 2026 | $15.00B | $2.47B | $3.58B | $3.99B |
| Dec 31, 2025 | $16.62B | $2.58B | $3.90B | $4.54B |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $17.40B Oct 30, 2026
- Latest report · revenue estimate
- $17.32B Oct 30, 2026
- Latest report · revenue vs estimate
- Above estimate Oct 30, 2026
- Latest report · EPS vs estimate
- Above estimate Oct 30, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Oct 30, 2026 | $17.40B | $17.32B | $3.8200 | $3.7300 |
| Jul 31, 2026 | $16.99B | $16.80B | $3.6500 | $3.6100 |
| Apr 29, 2026 | $15.00B | $14.72B | $2.6500 | $2.5900 |
| Feb 4, 2026 | $16.62B | $16.41B | $2.7100 | $2.6500 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | $17.40B | $4.22B | $2.38 (diluted) |
| Q2 FY2026 | $16.99B | $3.61B | $2.04 (diluted) |
| Q1 FY2026 | $15.00B | $695M | $0.39 (diluted) |
| Q4 FY2025 | $16.62B | $1.82B | $1.02 (diluted) |
What are the financial strengths and risks for AbbVie (ABBV)?
Short answer
Cash and short-term investments were $10.77B at the Sep 30, 2026 balance-sheet date. Operating cash flow was $7.61B for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered).
AbbVie consistently produces positive operating cash flow, and capital spending is modest relative to that inflow. Cash has moved unevenly and ended below its opening level across the reported window, yet cash generation remained resilient even when accounting earnings weakened.
Debt substantially exceeds cash and investments, while short-term liquidity ratios sit below full coverage. Strong gross and operating profitability help support that capital structure, but any sustained erosion in Skyrizi or Rinvoq sales, or another sharp rise in research costs without corresponding commercial output, would reduce the cushion. The quality screen is strong, while the distress screen offers a less emphatic signal.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $7.61B Sep 30, 2026
- Previous quarter · operating cash flow
- $3.44B Jun 30, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Sep 30, 2026 | $7.61B | −$301.00M |
| Jun 30, 2026 | $3.44B | −$322.00M |
| Mar 31, 2026 | $3.83B | −$265.00M |
| Dec 31, 2025 | $5.22B | −$329.00M |
How to read these figures
Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.
What should you watch next at AbbVie (ABBV)?
Short answer · as of
The next earnings report is expected on Feb 3, 2027.
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered).
The next earnings report should show whether revenue can continue advancing while operating profit and cash generation hold their recent recovery. The most useful confirmation would be continued commercial strength from Skyrizi and Rinvoq without renewed compression from research and selling costs.
Consensus expects revenue and earnings to expand over the coming years, and recent results have generally cleared expectations. That raises the execution bar: watch the reported product mix, operating margin, cash balance and debt together rather than treating an earnings beat as sufficient evidence on its own.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
And we expect to deliver top-tier growth again next year.
Robert Michael ·
How does AbbVie compare with its peers?
Short answer
AbbVie's score ranks 10th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered).
AbbVie's distinguishing feature is the combination of large immunology franchises with a broad set of established specialty medicines, including therapeutic Botox, Vraylar and oncology treatments. That makes it less dependent on a lone experimental pipeline than a narrow biotechnology company, yet more concentrated in Skyrizi and Rinvoq than the breadth of its therapeutic list might suggest.
Its cash profile also differs from that of a development-stage drug maker: operations already generate substantial cash, while the main financial constraint is leverage rather than recurring cash burn. The comparison that matters is therefore commercial durability under a heavy debt load, not simply the breadth of the pipeline.
| Company | Price | Market value | Score |
|---|---|---|---|
| $1434.26 Nov 16, 2026 | $1.35T | 98 5-pillar Nov 16, 2026 | |
| $48.39 Nov 16, 2026 | $116B | 91 5-pillar Nov 16, 2026 | |
| $62.93 Nov 16, 2026 | $129B | 90 5-pillar Nov 16, 2026 | |
| $184.02 Nov 16, 2026 | $285B | 87 5-pillar Nov 16, 2026 | |
| $160.20 Nov 16, 2026 | $303B | 86 5-pillar Nov 16, 2026 | |
| $41.60 Nov 16, 2026 | $183B | 86 5-pillar Nov 16, 2026 | |
| $462.32 Nov 16, 2026 | $250B | 86 5-pillar Nov 16, 2026 | |
| $282.55 Nov 16, 2026 | $680B | 84 5-pillar Nov 16, 2026 | |
| $50.41 Nov 16, 2026 | $101B | 84 5-pillar Nov 16, 2026 | |
| AbbVie (ABBV) — this page | $294.67 | $521B | 81 |
| $412.02 Nov 16, 2026 | $369B | 75 5-pillar Nov 16, 2026 | |
| $167.58 Nov 16, 2026 | $208B | 74 5-pillar Nov 16, 2026 | |
| $144.46 Nov 16, 2026 | $356B | 72 5-pillar Nov 16, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $275.00 – $340.00
- Consensus target
- $313.80
- Median target
- $315.00
Consensus record · Captured .
Measured against a quoted price of $294.67 (as of Nov 16, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 12, 2026
- Transactions
- 13
- Identified insiders
- 4
- Purchases
- 0
- Sales
- 2
- Other transactions
- 11
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 60.9% Period end Sep 30, 2026
- Previous quarter · ownership
- 76.1% Prior to period end Sep 30, 2026
- Reporting holders
- 3,893 Period end Sep 30, 2026
- Previous quarter · holders
- 4,369 Prior to period end Sep 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Blackrock, INC. | 148,974,939 |
| Vanguard Capital Management LLC | 115,676,728 |
| State Street Corp | 82,815,387 |
| Vanguard Portfolio Management LLC | 49,001,331 |
| Geode Capital Management, LLC | 47,503,777 |
Tracked investors
Which of the 16 named investors we follow held ABBV in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0% | $0 | Sold out (was $2.96M) |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about AbbVie (ABBV)?
What Investors Ask About AbbVie (ABBV) — Healthcare
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered); the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How dependent is AbbVie on Skyrizi and Rinvoq?
Skyrizi is AbbVie's largest reported product franchise, and Rinvoq is also materially larger than Humira in the current mix. Their combined durability is therefore central to revenue growth and to the success of AbbVie's transition away from Humira dependence.
What does Humira's smaller role mean for AbbVie?
Humira is no longer the dominant product in the reported mix; Skyrizi and Rinvoq have moved ahead of it. AbbVie's results now depend more on sustaining those successor franchises than on preserving Humira's former scale.
Why can AbbVie's research spending make earnings volatile?
Research expense has varied sharply across reported periods, and the elevated period coincided with an operating loss even though operating cash flow stayed positive. That separation means reported earnings can swing more dramatically than the underlying cash inflow.
Can Skyrizi-led cash generation support AbbVie's debt load?
Operating cash flow is substantial and persistent, but debt remains far larger than cash and investments. Support for the balance sheet therefore depends on continued portfolio cash generation, especially from Skyrizi and Rinvoq, rather than cash reserves alone.
What is the ABBV stock price today?
The last price recorded for AbbVie Inc. (ABBV), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the ABBV price target?
The analyst consensus price target for AbbVie Inc. (ABBV), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Reviewed by Sedat ANAK, Founder and Editor-in-Chief, on 2026-11-07.
Sources: the source register lists the 83 figures on this page — 2 from SEC filings and earnings calls, 72 from Financial Modeling Prep (FMP), 2 with no recorded source, 5 computed by us, formula shown in the register and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-12), by section of the research
ETFs that hold ABBV
Funds in our ETF coverage that list ABBV among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
